The Cerebral Vasospasm Market is segmented according to diagnosis, treatment, end user, and region. Market Research Future reports that the market size reached USD 2.41 billion in 2024 and could reach USD 4.745 billion by 2035, representing a CAGR of 6.35% from 2025 to 2035.

By diagnosis, the market includes computed tomography angiography, digital subtraction angiography, magnetic resonance angiography, and transcranial Doppler. Digital subtraction angiography is a significant segment because of its accuracy and ability to visualize cerebral vessels in detail. Transcranial Doppler is also gaining importance as a non-invasive monitoring technology.

The treatment segment includes nimodipine, Triple-H therapy, balloon angioplasty, vasopressors, inotropes, thrombolytic agents, and anti-inflammatory agents. Nimodipine is an established treatment option, while endovascular techniques are becoming increasingly important in complex cases.

By end user, hospitals represent the largest segment, followed by clinics, ambulatory surgical centers, trauma centers, and emergency departments. Hospitals benefit from specialized neurological departments and advanced imaging and intervention facilities.

Major companies associated with the broader market include Bristol-Myers Squibb, Amgen, Genentech, Eli Lilly and Company, AstraZeneca, Novartis, Pfizer, Bayer, and Sanofi.

Regional markets include North America, Europe, Asia-Pacific, and the Rest of the World. Increasing research activity, technological advancement, and demand for improved neurological care are expected to influence competition.

Gain valuable insights through comprehensive industry analysis:

Nootropic Supplements Market Trends

Endometriosis Treatment Market Growth

China Electric Wheelchair Market Demand

France Refurbished Medical Devices Market Volume

Germany Sexual Wellness Market Forecast